<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Bryce Foster | Leth Foley | Activity</title>
	<link>https://brycefoster.com/members/marblevase36/activity/</link>
	<atom:link href="https://brycefoster.com/members/marblevase36/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Leth Foley.</description>
	<lastBuildDate>Sat, 16 May 2026 10:40:51 +0000</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">b2e6eeb5ad82db4208cb6e12564d3741</guid>
				<title>Leth Foley posted an update: Exploring GLP-1 Drug Alternatives in the USA: A Comprehensive [&#133;]</title>
				<link>https://brycefoster.com/activity/p/1478821/</link>
				<pubDate>Wed, 25 Mar 2026 03:16:41 +0000</pubDate>

									<content:encoded><![CDATA[<p>Exploring GLP-1 Drug Alternatives in the USA: A Comprehensive Guide</p>
<p>The landscape of metabolic health and weight management has actually been transformed by the arrival of GLP-1 receptor agonists (RAs). Medications like Ozempic, Wegovy, Mounjaro, and Zepbound have actually become home names, praised for their efficacy in treating Type 2&hellip;<span class="activity-read-more" id="activity-read-more-1478821"><a href="https://brycefoster.com/activity/p/1478821/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">4ae4e165994ad533891b9a74327c5caa</guid>
				<title>Leth Foley became a registered member</title>
				<link>https://brycefoster.com/activity/p/1478780/</link>
				<pubDate>Wed, 25 Mar 2026 03:11:51 +0000</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>